View ValuationVimta Labs 将来の成長Future 基準チェック /06現在、 Vimta Labsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長25.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 15New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Reported Earnings • May 07Full year 2026 earnings released: EPS: ₹17.40 (vs ₹15.01 in FY 2025)Full year 2026 results: EPS: ₹17.40 (up from ₹15.01 in FY 2025). Revenue: ₹4.16b (up 21% from FY 2025). Net income: ₹775.1m (up 16% from FY 2025). Profit margin: 19% (in line with FY 2025). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 07Vimta Labs Limited announces Annual dividend, payable on July 08, 2026Vimta Labs Limited announced Annual dividend of INR 2.0000 per share payable on July 08, 2026, ex-date on June 18, 2026 and record date on June 18, 2026.お知らせ • May 06Vimta Labs Limited, Annual General Meeting, Jun 25, 2026Vimta Labs Limited, Annual General Meeting, Jun 25, 2026.Reported Earnings • Jan 29Third quarter 2026 earnings released: EPS: ₹3.96 (vs ₹3.93 in 3Q 2025)Third quarter 2026 results: EPS: ₹3.96 (up from ₹3.93 in 3Q 2025). Revenue: ₹1.00b (up 12% from 3Q 2025). Net income: ₹175.9m (flat on 3Q 2025). Profit margin: 18% (down from 20% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.Buy Or Sell Opportunity • Jan 07Now 21% overvaluedOver the last 90 days, the stock has fallen 14% to ₹617. The fair value is estimated to be ₹510, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.Buy Or Sell Opportunity • Dec 22Now 20% overvaluedOver the last 90 days, the stock has fallen 18% to ₹618. The fair value is estimated to be ₹515, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.Buy Or Sell Opportunity • Nov 25Now 20% overvaluedOver the last 90 days, the stock has fallen 2.5% to ₹616. The fair value is estimated to be ₹513, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.Reported Earnings • Nov 04Second quarter 2026 earnings released: EPS: ₹4.46 (vs ₹3.84 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.46 (up from ₹3.84 in 2Q 2025). Revenue: ₹1.05b (up 23% from 2Q 2025). Net income: ₹199.2m (up 17% from 2Q 2025). Profit margin: 19% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Sep 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹763, the stock trades at a trailing P/E ratio of 47.3x. Average trailing P/E is 41x in the Life Sciences industry in India. Total returns to shareholders of 332% over the past three years.Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹656, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 53x in the Life Sciences industry in India. Total returns to shareholders of 228% over the past three years.Reported Earnings • Jul 18First quarter 2026 earnings released: EPS: ₹4.25 (vs ₹2.77 in 1Q 2025)First quarter 2026 results: EPS: ₹4.25 (up from ₹2.77 in 1Q 2025). Revenue: ₹993.1m (up 22% from 1Q 2025). Net income: ₹188.9m (up 54% from 1Q 2025). Profit margin: 19% (up from 15% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Jun 12New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.お知らせ • Jun 07Vimta Labs Limited Approves Dividend for the Financial Year Ended March 31, 2025Vimta Labs Limited announced at annual general meeting held on June 6, 2025, the shareholders approved to declare a dividend of INR 2 per equity share for the financial year ended March 31, 2025.Upcoming Dividend • May 23Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 30 May 2025. Payment date: 16 June 2025. Payout ratio is a comfortable 6.7% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.4%).お知らせ • May 16Vimta Labs Limited, Annual General Meeting, Jun 06, 2025Vimta Labs Limited, Annual General Meeting, Jun 06, 2025, at 10:00 Indian Standard Time.Reported Earnings • May 16Full year 2025 earnings released: EPS: ₹30.28 (vs ₹18.51 in FY 2024)Full year 2025 results: EPS: ₹30.28 (up from ₹18.51 in FY 2024). Revenue: ₹3.48b (up 9.1% from FY 2024). Net income: ₹667.6m (up 63% from FY 2024). Profit margin: 19% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 15+ 3 more updatesVimta Labs Limited to Report First Half, 2026 Results on Nov 14, 2025Vimta Labs Limited announced that they will report first half, 2026 results on Nov 14, 2025お知らせ • Apr 24Vimta Labs Limited to Report Q4, 2025 Results on Apr 28, 2025Vimta Labs Limited announced that they will report Q4, 2025 results on Apr 28, 2025Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹852, the stock trades at a trailing P/E ratio of 34.7x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 127% over the past three years.Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹998, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 198% over the past three years.Valuation Update With 7 Day Price Move • Feb 21Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹947, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 50x in the Life Sciences industry in India. Total returns to shareholders of 196% over the past three years.Recent Insider Transactions • Feb 19Key Executive recently sold ₹3.1m worth of stockOn the 12th of February, V. Vungal sold around 3k shares on-market at roughly ₹1,084 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.8m. V. has been a net seller over the last 12 months, reducing personal holdings by ₹4.2m.Recent Insider Transactions • Feb 14Key Executive recently sold ₹1.0m worth of stockOn the 6th of February, V. Vungal sold around 975 shares on-market at roughly ₹1,038 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.8m. This was V.'s only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹1,045, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 163% over the past three years.Reported Earnings • Jan 25Third quarter 2025 earnings released: EPS: ₹7.86 (vs ₹4.57 in 3Q 2024)Third quarter 2025 results: EPS: ₹7.86 (up from ₹4.57 in 3Q 2024). Revenue: ₹911.5m (up 12% from 3Q 2024). Net income: ₹175.2m (up 73% from 3Q 2024). Profit margin: 19% (up from 12% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 24Vimta Labs Limited Appoints Siva Rama Krishna Kambhampati as Chief Financial Officer, Effective 3 March, 2025Vimta Labs Limited announced that at the board meeting held on January 24, 2025 approved the appointment of Shri. Siva Rama Krishna Kambhampati as Chief Financial Officer of the Company with effect from 3 March, 2025. Shri. Siva Rama Krishna Kambhampati is a seasoned finance professional with experience in Strategic Financial planning, controlling, costing, treasury management and designing internal controls. Experienced in working with cross functional and cross-cultural teams. He has an overall experience of 15 years and has worked with various listed and unlisted companies.お知らせ • Jan 20Vimta Labs Limited to Report Q3, 2025 Results on Jan 24, 2025Vimta Labs Limited announced that they will report Q3, 2025 results on Jan 24, 2025Valuation Update With 7 Day Price Move • Jan 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹826, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 95% over the past three years.New Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risk Significant insider selling over the past 3 months (₹21m sold).お知らせ • Dec 04Vimta Labs Limited Announces Resignation of Rama Narahai Naidu Dodda as Chief Financial Officer, Effective 10 December 2024Vimta Labs Limited announced that Shri. Rama Narahai Naidu Dodda, Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), has resigned from the services of the Company, with effect from close of business hours on 10 December 2024, as he wants to pursue career opportunities outside Vimta Labs Limited.Recent Insider Transactions • Dec 03Insider recently sold ₹5.8m worth of stockOn the 25th of November, Vasireddi Prasad sold around 7k shares on-market at roughly ₹828 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹26m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹898, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 143% over the past three years.New Risk • Nov 21New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹9.8m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.7% average weekly change). Significant insider selling over the past 3 months (₹9.8m sold).Recent Insider Transactions • Nov 21Insider recently sold ₹3.8m worth of stockOn the 14th of November, Vasireddi Prasad sold around 5k shares on-market at roughly ₹759 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹19m more than they bought in the last 12 months.Reported Earnings • Nov 09Second quarter 2025 earnings released: EPS: ₹7.68 (vs ₹2.85 in 2Q 2024)Second quarter 2025 results: EPS: ₹7.68 (up from ₹2.85 in 2Q 2024). Revenue: ₹854.3m (up 16% from 2Q 2024). Net income: ₹170.2m (up 169% from 2Q 2024). Profit margin: 20% (up from 8.6% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.0% average weekly change).Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹693, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 98% over the past three years.お知らせ • Nov 05Vimta Labs Limited to Report Q2, 2025 Results on Nov 08, 2024Vimta Labs Limited announced that they will report Q2, 2025 results on Nov 08, 2024お知らせ • Oct 11Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.Thyrocare Technologies Limited (BSE:539871) entered into Business Transfer Agreement to acquire Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on August 30, 2024. A cash consideration of INR 70 million will be paid by Thyrocare Technologies Limited. For the period ended March 31, 2024 Diagnostics and and pathological services business of Virnta Labs Limited had revenue of INR 296.67 million. Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on October 11, 2024.New Risk • Sep 19New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹3.5m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Significant insider selling over the past 3 months (₹3.5m sold).Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹607, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 46x in the Life Sciences industry in India. Total returns to shareholders of 111% over the past three years.お知らせ • Jul 18Vimta Labs Limited Approves Dividend for the Year Ended March 31, 2024Vimta Labs Limited announced that at its AGM held on July 18, 2024, shareholders approved the dividend of INR 2 per equity shares for the financial year ended March 31, 2024.お知らせ • Jul 12Vimta Labs Limited to Report Q1, 2025 Results on Jul 17, 2024Vimta Labs Limited announced that they will report Q1, 2025 results on Jul 17, 2024Upcoming Dividend • Jul 05Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 11% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%).Recent Insider Transactions • Jun 28Insider recently sold ₹3.5m worth of stockOn the 21st of June, Vasireddi Prasad sold around 7k shares on-market at roughly ₹493 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹35m more than they bought in the last 12 months.Reported Earnings • Jun 26Full year 2024 earnings released: EPS: ₹18.51 (vs ₹21.77 in FY 2023)Full year 2024 results: EPS: ₹18.51 (down from ₹21.77 in FY 2023). Revenue: ₹3.19b (flat on FY 2023). Net income: ₹410.1m (down 15% from FY 2023). Profit margin: 13% (down from 15% in FY 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 23Vimta Labs Limited, Annual General Meeting, Jul 18, 2024Vimta Labs Limited, Annual General Meeting, Jul 18, 2024, at 10:00 Indian Standard Time.Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹18.51 (vs ₹21.77 in FY 2023)Full year 2024 results: EPS: ₹18.51 (down from ₹21.77 in FY 2023). Revenue: ₹3.22b (up 1.0% from FY 2023). Net income: ₹410.1m (down 15% from FY 2023). Profit margin: 13% (down from 15% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 25Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹559, the stock trades at a trailing P/E ratio of 30x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 125% over the past three years.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹433, the stock trades at a trailing P/E ratio of 23.2x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 165% over the past three years.Recent Insider Transactions • Feb 28President recently sold ₹982k worth of stockOn the 23rd of February, Suresh Kumar sold around 2k shares on-market at roughly ₹491 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Suresh's only on-market trade for the last 12 months.Reported Earnings • Feb 01Third quarter 2024 earnings released: EPS: ₹4.57 (vs ₹4.62 in 3Q 2023)Third quarter 2024 results: EPS: ₹4.57 (down from ₹4.62 in 3Q 2023). Revenue: ₹825.7m (up 6.7% from 3Q 2023). Net income: ₹101.3m (down 1.1% from 3Q 2023). Profit margin: 12% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 20Vimta Labs Limited to Report Q3, 2024 Results on Jan 31, 2024Vimta Labs Limited announced that they will report Q3, 2024 results on Jan 31, 2024Reported Earnings • Nov 01Second quarter 2024 earnings released: EPS: ₹2.85 (vs ₹5.97 in 2Q 2023)Second quarter 2024 results: EPS: ₹2.85 (down from ₹5.97 in 2Q 2023). Revenue: ₹754.5m (down 5.5% from 2Q 2023). Net income: ₹63.3m (down 52% from 2Q 2023). Profit margin: 8.4% (down from 17% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹492, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 23x in the Life Sciences industry in India. Total returns to shareholders of 276% over the past three years.Valuation Update With 7 Day Price Move • Aug 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹581, the stock trades at a trailing P/E ratio of 26.6x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 444% over the past three years.Recent Insider Transactions • Aug 13Insider recently sold ₹4.9m worth of stockOn the 10th of August, Praveena Vasireddi sold around 10k shares on-market at roughly ₹490 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹24m more than they bought in the last 12 months.Reported Earnings • Jul 29First quarter 2024 earnings released: EPS: ₹5.51 (vs ₹5.45 in 1Q 2023)First quarter 2024 results: EPS: ₹5.51 (up from ₹5.45 in 1Q 2023). Revenue: ₹840.7m (up 6.2% from 1Q 2023). Net income: ₹122.0m (up 1.3% from 1Q 2023). Profit margin: 14% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹471, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 31x in the Life Sciences industry in India. Total returns to shareholders of 419% over the past three years.お知らせ • Jun 29Vimta Labs Limited Declares Dividend for the Financial Year Ended March 31, 2023Vimta Labs Limited at its 33rd Annual General Meeting held on 28 June 2023, declared a dividend of INR 2 per equity share for the financial year ended March 31, 2023.Upcoming Dividend • Jun 14Upcoming dividend of ₹2.00 per share at 0.5% yieldEligible shareholders must have bought the stock before 21 June 2023. Payment date: 07 July 2023. Payout ratio is a comfortable 9.2% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%).お知らせ • Jun 02+ 3 more updatesVimta Labs Limited to Report Q4, 2024 Results on May 30, 2024Vimta Labs Limited announced that they will report Q4, 2024 results on May 30, 2024Reported Earnings • May 05Full year 2023 earnings released: EPS: ₹21.77 (vs ₹18.70 in FY 2022)Full year 2023 results: EPS: ₹21.77 (up from ₹18.70 in FY 2022). Revenue: ₹3.22b (up 15% from FY 2022). Net income: ₹481.7m (up 17% from FY 2022). Profit margin: 15% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 75% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 04+ 1 more updateVimta Labs Limited Recommends Dividend for the Financial Year 2022-2023Vimta Labs Limited recommends Dividend of INR 2 (Rupees two only) per share with face value of INR 2 each for the financial year 2022-2023, subject to approval of shareholders in their ensuing Annual General Meeting.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹337, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 199% over the past three years.Reported Earnings • Jan 30Third quarter 2023 earnings released: EPS: ₹4.62 (vs ₹5.28 in 3Q 2022)Third quarter 2023 results: EPS: ₹4.62 (down from ₹5.28 in 3Q 2022). Revenue: ₹773.8m (up 15% from 3Q 2022). Net income: ₹102.4m (down 12% from 3Q 2022). Profit margin: 13% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 51% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Nov 26President recently sold ₹2.3m worth of stockOn the 21st of November, Suresh Kumar sold around 5k shares on-market at roughly ₹463 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹16m. This was Suresh's only on-market trade for the last 12 months.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Yadagiri Pendri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹481, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 35x in the Life Sciences industry in India. Total returns to shareholders of 400% over the past three years.Recent Insider Transactions • Nov 05Insider recently sold ₹16m worth of stockOn the 2nd of November, Rajya Vasireddi sold around 40k shares on-market at roughly ₹408 per share. This transaction amounted to 95% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Board Change • Aug 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Yadagiri Pendri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 26First quarter 2023 earnings released: EPS: ₹5.45 (vs ₹3.65 in 1Q 2022)First quarter 2023 results: EPS: ₹5.45 (up from ₹3.65 in 1Q 2022). Revenue: ₹800.2m (up 30% from 1Q 2022). Net income: ₹120.4m (up 49% from 1Q 2022). Profit margin: 15% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year whereas the company’s share price has increased by 56% per year.Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹371, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 33x in the Life Sciences industry in India. Total returns to shareholders of 112% over the past three years.Upcoming Dividend • Jun 09Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 16 June 2022. Payment date: 25 July 2022. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.8%). In line with average of industry peers (0.7%).お知らせ • May 31+ 4 more updatesVimta Labs Limited Recommends Dividend for the Financial Year Ended March 31, 2022The Annual General Meeting of the members of Vimta Labs Limited will be held on, June 25, 2022. At the meeting, the Board of directors recommended dividend of INR 2 per share for the financial year ended March 31, 2022. The dividend will be paid to all the shareholders whose names were appearing in the register of members as on June 18, 2022, being the record date fixed for this purpose.Reported Earnings • May 15Full year 2022 earnings released: EPS: ₹18.70 (vs ₹9.68 in FY 2021)Full year 2022 results: EPS: ₹18.70. Revenue: ₹279.7m (down 87% from FY 2021). Net income: ₹41.3m (down 81% from FY 2021). Profit margin: 15% (up from 10% in FY 2021). The increase in margin was driven by lower expenses.お知らせ • May 14Vimta Labs Limited Recommends Dividend for the Year 2021-2022Vimta Labs Limited Recommended Dividend of INR 2 per share with face value of INR 2 each for the financial year 2021-2022; subject to approval of shareholders in their upcoming Annual General Meeting.お知らせ • May 13Vimta Labs Limited, Annual General Meeting, Jun 25, 2022Vimta Labs Limited, Annual General Meeting, Jun 25, 2022, at 10:00 Indian Standard Time. Agenda: To consider the recommendation of dividend for the financial year 2021-2022; to consider the re-appointment of Smt. Y Prameela Rani as an Independent Director for the second and final term of five years from 1st December 2022 to 30th November 2027; and to recommended reappointment of Statutory Auditors M/s. Gattamaneni & Co, Chartered Accountants for second and final term of five years.お知らせ • May 05Vimta Labs Limited to Report Q4, 2022 Results on May 12, 2022Vimta Labs Limited announced that they will report Q4, 2022 results on May 12, 2022Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹383, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 98% over the past three years.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹317, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 34x in the Life Sciences industry in India. Total returns to shareholders of 82% over the past three years.Reported Earnings • Jan 22Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹5.28 (up from ₹3.65 in 3Q 2021). Revenue: ₹680.5m (up 16% from 3Q 2021). Net income: ₹116.8m (up 45% from 3Q 2021). Profit margin: 17% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 22% per year whereas the company’s share price has increased by 17% per year.Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹422, the stock trades at a trailing P/E ratio of 27.7x. Average trailing P/E is 32x in the Life Sciences industry in India. Total returns to shareholders of 69% over the past three years.Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹350, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 23x in the Life Sciences industry in India. Total returns to shareholders of 34% over the past three years.Reported Earnings • Oct 24Second quarter 2022 earnings released: EPS ₹4.41 (vs ₹3.41 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹756.2m (up 27% from 2Q 2021). Net income: ₹97.4m (up 29% from 2Q 2021). Profit margin: 13% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has increased by 5% per year and the company’s share price has also increased by 5% per year.Reported Earnings • Jul 23First quarter 2022 earnings released: EPS ₹3.65 (vs ₹0.88 loss in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹615.3m (up 88% from 1Q 2021). Net income: ₹80.7m (up ₹100.1m from 1Q 2021). Profit margin: 13% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jul 09Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹324, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 52% over the past three years.Upcoming Dividend • Jun 18Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 25 June 2021. Payment date: 04 August 2021. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.6%). Higher than average of industry peers (0.3%). このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Vimta Labs は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:524394 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20264,0737754731,471N/A12/31/20253,939747N/AN/AN/A9/30/20253,8527462771,207N/A6/30/20253,681717N/AN/AN/A3/31/20253,454668151946N/A12/31/20243,530546N/AN/AN/A9/30/20243,376493143829N/A6/30/20243,176411N/AN/AN/A3/31/20242,896488-157609N/A12/31/20233,212413N/AN/AN/A9/30/20233,1694151765N/A6/30/20233,234483N/AN/AN/A3/31/20233,190482381879N/A12/31/20223,109473N/AN/AN/A9/30/20223,009488367677N/A6/30/20222,965453N/AN/AN/A3/31/20222,787413203591N/A12/31/20212,644372N/AN/AN/A9/30/20212,5573363496N/A6/30/20212,396314N/AN/AN/A3/31/20212,11021441372N/A12/31/20201,945137N/AN/AN/A9/30/20201,873104176357N/A6/30/20201,69437N/AN/AN/A3/31/20201,8116886243N/A12/31/20191,914136N/AN/AN/A9/30/20191,906140N/A270N/A6/30/20192,025200N/AN/AN/A3/31/20192,130253N/A391N/A12/31/20182,126236N/AN/AN/A9/30/20182,071245N/AN/AN/A6/30/20181,970218N/AN/AN/A3/31/20181,836164N/A334N/A12/31/20171,693134N/AN/AN/A9/30/20171,602104N/AN/AN/A6/30/20171,55283N/AN/AN/A3/31/20171,538106N/A239N/A12/31/20161,46894N/AN/AN/A9/30/20161,37674N/AN/AN/A6/30/20161,34479N/AN/AN/A3/31/20161,24764N/A-10N/A12/31/20151,20263N/AN/AN/A9/30/20151,15759N/AN/AN/A6/30/20151,06845N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 524394の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 524394の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 524394の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 524394の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 524394の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 524394の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 07:44終値2026/05/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vimta Labs Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Rohit Bhat360 ONE Capital Market Private LimitedVijay MadunalaFirstCall Research
New Risk • May 15New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Reported Earnings • May 07Full year 2026 earnings released: EPS: ₹17.40 (vs ₹15.01 in FY 2025)Full year 2026 results: EPS: ₹17.40 (up from ₹15.01 in FY 2025). Revenue: ₹4.16b (up 21% from FY 2025). Net income: ₹775.1m (up 16% from FY 2025). Profit margin: 19% (in line with FY 2025). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 07Vimta Labs Limited announces Annual dividend, payable on July 08, 2026Vimta Labs Limited announced Annual dividend of INR 2.0000 per share payable on July 08, 2026, ex-date on June 18, 2026 and record date on June 18, 2026.
お知らせ • May 06Vimta Labs Limited, Annual General Meeting, Jun 25, 2026Vimta Labs Limited, Annual General Meeting, Jun 25, 2026.
Reported Earnings • Jan 29Third quarter 2026 earnings released: EPS: ₹3.96 (vs ₹3.93 in 3Q 2025)Third quarter 2026 results: EPS: ₹3.96 (up from ₹3.93 in 3Q 2025). Revenue: ₹1.00b (up 12% from 3Q 2025). Net income: ₹175.9m (flat on 3Q 2025). Profit margin: 18% (down from 20% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
Buy Or Sell Opportunity • Jan 07Now 21% overvaluedOver the last 90 days, the stock has fallen 14% to ₹617. The fair value is estimated to be ₹510, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.
Buy Or Sell Opportunity • Dec 22Now 20% overvaluedOver the last 90 days, the stock has fallen 18% to ₹618. The fair value is estimated to be ₹515, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.
Buy Or Sell Opportunity • Nov 25Now 20% overvaluedOver the last 90 days, the stock has fallen 2.5% to ₹616. The fair value is estimated to be ₹513, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.
Reported Earnings • Nov 04Second quarter 2026 earnings released: EPS: ₹4.46 (vs ₹3.84 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.46 (up from ₹3.84 in 2Q 2025). Revenue: ₹1.05b (up 23% from 2Q 2025). Net income: ₹199.2m (up 17% from 2Q 2025). Profit margin: 19% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Sep 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹763, the stock trades at a trailing P/E ratio of 47.3x. Average trailing P/E is 41x in the Life Sciences industry in India. Total returns to shareholders of 332% over the past three years.
Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹656, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 53x in the Life Sciences industry in India. Total returns to shareholders of 228% over the past three years.
Reported Earnings • Jul 18First quarter 2026 earnings released: EPS: ₹4.25 (vs ₹2.77 in 1Q 2025)First quarter 2026 results: EPS: ₹4.25 (up from ₹2.77 in 1Q 2025). Revenue: ₹993.1m (up 22% from 1Q 2025). Net income: ₹188.9m (up 54% from 1Q 2025). Profit margin: 19% (up from 15% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Jun 12New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
お知らせ • Jun 07Vimta Labs Limited Approves Dividend for the Financial Year Ended March 31, 2025Vimta Labs Limited announced at annual general meeting held on June 6, 2025, the shareholders approved to declare a dividend of INR 2 per equity share for the financial year ended March 31, 2025.
Upcoming Dividend • May 23Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 30 May 2025. Payment date: 16 June 2025. Payout ratio is a comfortable 6.7% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.4%).
お知らせ • May 16Vimta Labs Limited, Annual General Meeting, Jun 06, 2025Vimta Labs Limited, Annual General Meeting, Jun 06, 2025, at 10:00 Indian Standard Time.
Reported Earnings • May 16Full year 2025 earnings released: EPS: ₹30.28 (vs ₹18.51 in FY 2024)Full year 2025 results: EPS: ₹30.28 (up from ₹18.51 in FY 2024). Revenue: ₹3.48b (up 9.1% from FY 2024). Net income: ₹667.6m (up 63% from FY 2024). Profit margin: 19% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 15+ 3 more updatesVimta Labs Limited to Report First Half, 2026 Results on Nov 14, 2025Vimta Labs Limited announced that they will report first half, 2026 results on Nov 14, 2025
お知らせ • Apr 24Vimta Labs Limited to Report Q4, 2025 Results on Apr 28, 2025Vimta Labs Limited announced that they will report Q4, 2025 results on Apr 28, 2025
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹852, the stock trades at a trailing P/E ratio of 34.7x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 127% over the past three years.
Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹998, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 198% over the past three years.
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹947, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 50x in the Life Sciences industry in India. Total returns to shareholders of 196% over the past three years.
Recent Insider Transactions • Feb 19Key Executive recently sold ₹3.1m worth of stockOn the 12th of February, V. Vungal sold around 3k shares on-market at roughly ₹1,084 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.8m. V. has been a net seller over the last 12 months, reducing personal holdings by ₹4.2m.
Recent Insider Transactions • Feb 14Key Executive recently sold ₹1.0m worth of stockOn the 6th of February, V. Vungal sold around 975 shares on-market at roughly ₹1,038 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.8m. This was V.'s only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹1,045, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 163% over the past three years.
Reported Earnings • Jan 25Third quarter 2025 earnings released: EPS: ₹7.86 (vs ₹4.57 in 3Q 2024)Third quarter 2025 results: EPS: ₹7.86 (up from ₹4.57 in 3Q 2024). Revenue: ₹911.5m (up 12% from 3Q 2024). Net income: ₹175.2m (up 73% from 3Q 2024). Profit margin: 19% (up from 12% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 24Vimta Labs Limited Appoints Siva Rama Krishna Kambhampati as Chief Financial Officer, Effective 3 March, 2025Vimta Labs Limited announced that at the board meeting held on January 24, 2025 approved the appointment of Shri. Siva Rama Krishna Kambhampati as Chief Financial Officer of the Company with effect from 3 March, 2025. Shri. Siva Rama Krishna Kambhampati is a seasoned finance professional with experience in Strategic Financial planning, controlling, costing, treasury management and designing internal controls. Experienced in working with cross functional and cross-cultural teams. He has an overall experience of 15 years and has worked with various listed and unlisted companies.
お知らせ • Jan 20Vimta Labs Limited to Report Q3, 2025 Results on Jan 24, 2025Vimta Labs Limited announced that they will report Q3, 2025 results on Jan 24, 2025
Valuation Update With 7 Day Price Move • Jan 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹826, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 95% over the past three years.
New Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risk Significant insider selling over the past 3 months (₹21m sold).
お知らせ • Dec 04Vimta Labs Limited Announces Resignation of Rama Narahai Naidu Dodda as Chief Financial Officer, Effective 10 December 2024Vimta Labs Limited announced that Shri. Rama Narahai Naidu Dodda, Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), has resigned from the services of the Company, with effect from close of business hours on 10 December 2024, as he wants to pursue career opportunities outside Vimta Labs Limited.
Recent Insider Transactions • Dec 03Insider recently sold ₹5.8m worth of stockOn the 25th of November, Vasireddi Prasad sold around 7k shares on-market at roughly ₹828 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹26m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹898, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 143% over the past three years.
New Risk • Nov 21New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹9.8m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.7% average weekly change). Significant insider selling over the past 3 months (₹9.8m sold).
Recent Insider Transactions • Nov 21Insider recently sold ₹3.8m worth of stockOn the 14th of November, Vasireddi Prasad sold around 5k shares on-market at roughly ₹759 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹19m more than they bought in the last 12 months.
Reported Earnings • Nov 09Second quarter 2025 earnings released: EPS: ₹7.68 (vs ₹2.85 in 2Q 2024)Second quarter 2025 results: EPS: ₹7.68 (up from ₹2.85 in 2Q 2024). Revenue: ₹854.3m (up 16% from 2Q 2024). Net income: ₹170.2m (up 169% from 2Q 2024). Profit margin: 20% (up from 8.6% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.0% average weekly change).
Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹693, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 98% over the past three years.
お知らせ • Nov 05Vimta Labs Limited to Report Q2, 2025 Results on Nov 08, 2024Vimta Labs Limited announced that they will report Q2, 2025 results on Nov 08, 2024
お知らせ • Oct 11Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.Thyrocare Technologies Limited (BSE:539871) entered into Business Transfer Agreement to acquire Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on August 30, 2024. A cash consideration of INR 70 million will be paid by Thyrocare Technologies Limited. For the period ended March 31, 2024 Diagnostics and and pathological services business of Virnta Labs Limited had revenue of INR 296.67 million. Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on October 11, 2024.
New Risk • Sep 19New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹3.5m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Significant insider selling over the past 3 months (₹3.5m sold).
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹607, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 46x in the Life Sciences industry in India. Total returns to shareholders of 111% over the past three years.
お知らせ • Jul 18Vimta Labs Limited Approves Dividend for the Year Ended March 31, 2024Vimta Labs Limited announced that at its AGM held on July 18, 2024, shareholders approved the dividend of INR 2 per equity shares for the financial year ended March 31, 2024.
お知らせ • Jul 12Vimta Labs Limited to Report Q1, 2025 Results on Jul 17, 2024Vimta Labs Limited announced that they will report Q1, 2025 results on Jul 17, 2024
Upcoming Dividend • Jul 05Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 11% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%).
Recent Insider Transactions • Jun 28Insider recently sold ₹3.5m worth of stockOn the 21st of June, Vasireddi Prasad sold around 7k shares on-market at roughly ₹493 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹35m more than they bought in the last 12 months.
Reported Earnings • Jun 26Full year 2024 earnings released: EPS: ₹18.51 (vs ₹21.77 in FY 2023)Full year 2024 results: EPS: ₹18.51 (down from ₹21.77 in FY 2023). Revenue: ₹3.19b (flat on FY 2023). Net income: ₹410.1m (down 15% from FY 2023). Profit margin: 13% (down from 15% in FY 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 23Vimta Labs Limited, Annual General Meeting, Jul 18, 2024Vimta Labs Limited, Annual General Meeting, Jul 18, 2024, at 10:00 Indian Standard Time.
Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹18.51 (vs ₹21.77 in FY 2023)Full year 2024 results: EPS: ₹18.51 (down from ₹21.77 in FY 2023). Revenue: ₹3.22b (up 1.0% from FY 2023). Net income: ₹410.1m (down 15% from FY 2023). Profit margin: 13% (down from 15% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹559, the stock trades at a trailing P/E ratio of 30x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 125% over the past three years.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹433, the stock trades at a trailing P/E ratio of 23.2x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 165% over the past three years.
Recent Insider Transactions • Feb 28President recently sold ₹982k worth of stockOn the 23rd of February, Suresh Kumar sold around 2k shares on-market at roughly ₹491 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Suresh's only on-market trade for the last 12 months.
Reported Earnings • Feb 01Third quarter 2024 earnings released: EPS: ₹4.57 (vs ₹4.62 in 3Q 2023)Third quarter 2024 results: EPS: ₹4.57 (down from ₹4.62 in 3Q 2023). Revenue: ₹825.7m (up 6.7% from 3Q 2023). Net income: ₹101.3m (down 1.1% from 3Q 2023). Profit margin: 12% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 20Vimta Labs Limited to Report Q3, 2024 Results on Jan 31, 2024Vimta Labs Limited announced that they will report Q3, 2024 results on Jan 31, 2024
Reported Earnings • Nov 01Second quarter 2024 earnings released: EPS: ₹2.85 (vs ₹5.97 in 2Q 2023)Second quarter 2024 results: EPS: ₹2.85 (down from ₹5.97 in 2Q 2023). Revenue: ₹754.5m (down 5.5% from 2Q 2023). Net income: ₹63.3m (down 52% from 2Q 2023). Profit margin: 8.4% (down from 17% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹492, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 23x in the Life Sciences industry in India. Total returns to shareholders of 276% over the past three years.
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹581, the stock trades at a trailing P/E ratio of 26.6x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 444% over the past three years.
Recent Insider Transactions • Aug 13Insider recently sold ₹4.9m worth of stockOn the 10th of August, Praveena Vasireddi sold around 10k shares on-market at roughly ₹490 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹24m more than they bought in the last 12 months.
Reported Earnings • Jul 29First quarter 2024 earnings released: EPS: ₹5.51 (vs ₹5.45 in 1Q 2023)First quarter 2024 results: EPS: ₹5.51 (up from ₹5.45 in 1Q 2023). Revenue: ₹840.7m (up 6.2% from 1Q 2023). Net income: ₹122.0m (up 1.3% from 1Q 2023). Profit margin: 14% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹471, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 31x in the Life Sciences industry in India. Total returns to shareholders of 419% over the past three years.
お知らせ • Jun 29Vimta Labs Limited Declares Dividend for the Financial Year Ended March 31, 2023Vimta Labs Limited at its 33rd Annual General Meeting held on 28 June 2023, declared a dividend of INR 2 per equity share for the financial year ended March 31, 2023.
Upcoming Dividend • Jun 14Upcoming dividend of ₹2.00 per share at 0.5% yieldEligible shareholders must have bought the stock before 21 June 2023. Payment date: 07 July 2023. Payout ratio is a comfortable 9.2% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%).
お知らせ • Jun 02+ 3 more updatesVimta Labs Limited to Report Q4, 2024 Results on May 30, 2024Vimta Labs Limited announced that they will report Q4, 2024 results on May 30, 2024
Reported Earnings • May 05Full year 2023 earnings released: EPS: ₹21.77 (vs ₹18.70 in FY 2022)Full year 2023 results: EPS: ₹21.77 (up from ₹18.70 in FY 2022). Revenue: ₹3.22b (up 15% from FY 2022). Net income: ₹481.7m (up 17% from FY 2022). Profit margin: 15% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 75% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 04+ 1 more updateVimta Labs Limited Recommends Dividend for the Financial Year 2022-2023Vimta Labs Limited recommends Dividend of INR 2 (Rupees two only) per share with face value of INR 2 each for the financial year 2022-2023, subject to approval of shareholders in their ensuing Annual General Meeting.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹337, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 199% over the past three years.
Reported Earnings • Jan 30Third quarter 2023 earnings released: EPS: ₹4.62 (vs ₹5.28 in 3Q 2022)Third quarter 2023 results: EPS: ₹4.62 (down from ₹5.28 in 3Q 2022). Revenue: ₹773.8m (up 15% from 3Q 2022). Net income: ₹102.4m (down 12% from 3Q 2022). Profit margin: 13% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 51% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Nov 26President recently sold ₹2.3m worth of stockOn the 21st of November, Suresh Kumar sold around 5k shares on-market at roughly ₹463 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹16m. This was Suresh's only on-market trade for the last 12 months.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Yadagiri Pendri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹481, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 35x in the Life Sciences industry in India. Total returns to shareholders of 400% over the past three years.
Recent Insider Transactions • Nov 05Insider recently sold ₹16m worth of stockOn the 2nd of November, Rajya Vasireddi sold around 40k shares on-market at roughly ₹408 per share. This transaction amounted to 95% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Board Change • Aug 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Yadagiri Pendri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 26First quarter 2023 earnings released: EPS: ₹5.45 (vs ₹3.65 in 1Q 2022)First quarter 2023 results: EPS: ₹5.45 (up from ₹3.65 in 1Q 2022). Revenue: ₹800.2m (up 30% from 1Q 2022). Net income: ₹120.4m (up 49% from 1Q 2022). Profit margin: 15% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year whereas the company’s share price has increased by 56% per year.
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹371, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 33x in the Life Sciences industry in India. Total returns to shareholders of 112% over the past three years.
Upcoming Dividend • Jun 09Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 16 June 2022. Payment date: 25 July 2022. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.8%). In line with average of industry peers (0.7%).
お知らせ • May 31+ 4 more updatesVimta Labs Limited Recommends Dividend for the Financial Year Ended March 31, 2022The Annual General Meeting of the members of Vimta Labs Limited will be held on, June 25, 2022. At the meeting, the Board of directors recommended dividend of INR 2 per share for the financial year ended March 31, 2022. The dividend will be paid to all the shareholders whose names were appearing in the register of members as on June 18, 2022, being the record date fixed for this purpose.
Reported Earnings • May 15Full year 2022 earnings released: EPS: ₹18.70 (vs ₹9.68 in FY 2021)Full year 2022 results: EPS: ₹18.70. Revenue: ₹279.7m (down 87% from FY 2021). Net income: ₹41.3m (down 81% from FY 2021). Profit margin: 15% (up from 10% in FY 2021). The increase in margin was driven by lower expenses.
お知らせ • May 14Vimta Labs Limited Recommends Dividend for the Year 2021-2022Vimta Labs Limited Recommended Dividend of INR 2 per share with face value of INR 2 each for the financial year 2021-2022; subject to approval of shareholders in their upcoming Annual General Meeting.
お知らせ • May 13Vimta Labs Limited, Annual General Meeting, Jun 25, 2022Vimta Labs Limited, Annual General Meeting, Jun 25, 2022, at 10:00 Indian Standard Time. Agenda: To consider the recommendation of dividend for the financial year 2021-2022; to consider the re-appointment of Smt. Y Prameela Rani as an Independent Director for the second and final term of five years from 1st December 2022 to 30th November 2027; and to recommended reappointment of Statutory Auditors M/s. Gattamaneni & Co, Chartered Accountants for second and final term of five years.
お知らせ • May 05Vimta Labs Limited to Report Q4, 2022 Results on May 12, 2022Vimta Labs Limited announced that they will report Q4, 2022 results on May 12, 2022
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹383, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 37x in the Life Sciences industry in India. Total returns to shareholders of 98% over the past three years.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹317, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 34x in the Life Sciences industry in India. Total returns to shareholders of 82% over the past three years.
Reported Earnings • Jan 22Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹5.28 (up from ₹3.65 in 3Q 2021). Revenue: ₹680.5m (up 16% from 3Q 2021). Net income: ₹116.8m (up 45% from 3Q 2021). Profit margin: 17% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 22% per year whereas the company’s share price has increased by 17% per year.
Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹422, the stock trades at a trailing P/E ratio of 27.7x. Average trailing P/E is 32x in the Life Sciences industry in India. Total returns to shareholders of 69% over the past three years.
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹350, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 23x in the Life Sciences industry in India. Total returns to shareholders of 34% over the past three years.
Reported Earnings • Oct 24Second quarter 2022 earnings released: EPS ₹4.41 (vs ₹3.41 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹756.2m (up 27% from 2Q 2021). Net income: ₹97.4m (up 29% from 2Q 2021). Profit margin: 13% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has increased by 5% per year and the company’s share price has also increased by 5% per year.
Reported Earnings • Jul 23First quarter 2022 earnings released: EPS ₹3.65 (vs ₹0.88 loss in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹615.3m (up 88% from 1Q 2021). Net income: ₹80.7m (up ₹100.1m from 1Q 2021). Profit margin: 13% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jul 09Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹324, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 52% over the past three years.
Upcoming Dividend • Jun 18Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 25 June 2021. Payment date: 04 August 2021. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.6%). Higher than average of industry peers (0.3%).